News

News

Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy

Hanover, MD, and New York, NY, October 12, 2020 – The Sickle Cell Disease Association of America (SCDAA) and Aruvant Sciences are proud to announce

0 comments

Aruvant to Present at Investor and Scientific Conferences in October

NEW YORK and BASEL, Switzerland, Sept. 29, 2020 — Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment

0 comments

One-time Gene Therapy for Sickle Cell Disease

0 comments

Aruvant Appoints Dr. Palaniappan as Chief Technology Officer

Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than

0 comments

Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer

Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell

0 comments

Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a

0 comments

Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia ARU-1801 has been designed to deliver a

0 comments

Aruvant Appoints William Chou as Chief Executive Officer

Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe

0 comments

Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens Both patients exhibit evidence of sustained, stable, genetically-modified cells in blood and

0 comments

Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children’s Hospital Medical Center

BASEL, Switzerland and CINCINNATI November 26, 2018 | PRNewswire Roivant Sciences and Cincinnati Children’s Hospital Medical Center today announced the launch of Aruvant Sciences, a

0 comments